Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy.

@article{Blackledge2003GrowthFR,
  title={Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy.},
  author={George R. P. Blackledge},
  journal={The Journal of urology},
  year={2003},
  volume={170 6 Pt 2},
  pages={S77-83; discussion S83}
}
PURPOSE The development of effective, novel, targeted cancer therapies with minimal side effects has long been a goal in cancer research. A key group of targets identified for drug development consists of the receptor tyrosine kinases, which have pivotal roles in the growth factor signaling that is subverted in carcinogenesis and in the host processes, such as angiogenesis, involved in tumor progression. MATERIALS AND METHODS A literature review of the role of receptor tyrosine kinases in… CONTINUE READING